help button home button Endocrine Society JCEM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

Journal of Clinical Endocrinology & Metabolism Vol. 66, No. 5 964-967
doi:10.1210/jcem-66-5-964
Copyright © 1988 by the Endocrine Society.
This Article
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by MELIS, G. B.
Right arrow Articles by FIORETTI, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by MELIS, G. B.
Right arrow Articles by FIORETTI, P.

Restoration of Luteinizing Hormone Response to Naloxone in Postmenopausal Women by Chronic Administration of the Antidopaminergic Drug Veralipride*

GIAN BENEDETTO MELIS, ANGELO CAGNACCI, MARCO GAMBACCIANI, ANNA MARIA PAOLETTI, LAURA MOGGI and PIERO FIORETTI

Department of Obstetrics and Gynecology, University of Pisa School of Medicine 56100 Pisa, Italy

Address all correspondence and requests for reprints to: Dr. Gian Benedetto Melis, Department of Obstetrics and Gynecology, University of Pisa, Via Roma 67, Pisa, 56100 Italy.

To determine whether antidopaminergic drug administration may modify endogenous opioid activity at the hypothalamic-pituitary level, the effects of naloxone infusion (1.6 mg/h for 4 h) on LH secretion were studied in six postmenopausal women before and after administration of the potent antidopaminergic drug veralipride for 20 days. Before veralipride administration, the naloxone infusion did not alter LH secretion. Chronic administration of veralipride resulted in a significant (P < 0.01) decline in plasma LH levels. In addition, the naloxone infusion induced a significant (P < 0.05) increase in plasma LH levels, which reached values similar to those before veralipride administration.

These results demonstrate that in postmenopausal women the antidopaminergic drug veralipride can restore, at least in part, the activity of the endogenous opioid system. These findings suggest that endogenous opioid peptides may mediate the inhibitory effect exerted by chronic antidopaminergic drug administration on LH secretion in humans.

* This work was supported by the Consiglio Nazionale delle Ricerche (C.N.R.), Rome, Italy (Grants 86.00531.04 and 86.01787.56).

Received January 20, 1987.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 1988 by The Endocrine Society